Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer
Part of paid clinical trials in Phoenix, Arizona.
- Sponsor
- Arjun Balar, MD
- Study ID
- NCT03272217
- Phase
- PHASE2
- Status
- Terminated
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Atezolizumab — DRUGAtezolizumab 1200 mg (flat dose) IV every 21 days
- Bevacizumab — DRUGBevacizumab 15 mg/kg IV every 21 days
Study Details
This is a phase II study assessing the activity of bevacizumab combined with atezolizumab in metastatic urothelial carcinoma patients who are ineligible for cisplatin-based therapy.
Key Dates
- Start date
- Sep 13, 2017
- Status verified
- Dec 2024
- Primary completion
- May 27, 2021
- Completion
- Mar 17, 2022
Study Design
- Enrollment
- 16 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A - Atezolizumab + BevacizumabPatients will receive atezolizumab 1200 mg (flat dose) IV plus bevacizumab 15 mg/kg IV every 21 days
Primary Outcome Measure
Overall Survival (OS) Rate at 1 Year [ Time Frame: 1 years ]
Locations (8)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| University of Arizona at Dignity Health St. Joseph | Phoenix | Arizona | 85004 | - |
| Rush University Medical Center | Chicago | Illinois | 60612 | - |
| HealthPartners Institute | Minneapolis | Minnesota | 55440 | - |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | - |
| New York University Clinical Cancer Center | New York | New York | 10016 | - |
| Cleveland Clinic | Cleveland | Ohio | 44195 | - |
| West Cancer Center University of Tennessee | Memphis | Tennessee | 38120 | - |
| Froedtert & The Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | - |
Find similar trials in Phoenix, AZ
By condition
By research site
Related Studies
- Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderPHASE1/PHASE2 · Recruiting · Noah Hahn, M.D. · Phoenix, Arizona
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and RegistryRecruiting · Massive Bio, Inc. · Birmingham, Alabama
- A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2PHASE2 · Recruiting · Seagen, a wholly owned subsidiary of Pfizer · Gilbert, Arizona
- A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid TumorsPHASE1/PHASE2 · Recruiting · Bristol-Myers Squibb · Clovis, California